Home / Investors

Earnings Webcast Replay

PETVIVO Inc. announced it's recent quarterly earnings report via webcast.

Click To Watch









Why Invest With PetVivo?

Spryng™ with OsteoCushion™ Technology is within a booming industry that continues to increase in growth, need, and sales.

$4.8B Market

Osteoarthritis (OA) affects 1 out of 4 dogs and over half of all horses . This is an addressable opportunity in companion animal OA therapeutics market.

Large and Growing Market

68% of US households own a pet and stats show a $99B US pet spend as of 2020.

Positioned to Scale

New facility, positioned to scale, with capacity to produce up 500K units annually = up to 100M in revenue.


Learn about our goals, our team, and our ground-breaking product, Spryng™ with OsteoCushion™ Technology.

Click Here to scroll through PetVivo's corporate slide deck.

Petvivo Holdings, Inc. is a publicly traded company traded on the NASDAQ: PETV.


What is PetVivo Holdings, Inc.?

PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.  

PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of eighteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product Spryng™ with OsteoCushion™ Technology, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.

What is spryng™ with OsteoCushion™ Technology?

Spryng™ with OsteoCushion™ Technology is a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses.

Spryng™ uses precisely sized micro-particles for optimal joint spacing and for easy intra-articular injection with 18-23 gauge needles. Spryng™ particles are too large to seep through synovial membranes, allowing long duration of their slippery cushion effects to reinforce the joint's articular cartilage and ameliorate or preclude the cartilage defects that cause pain to limit motion.

What is the difference between PetVivo and spryng™ with OsteoCushion™ Technology?

PetVivo Holdings, Inc. is the name of our company.
Spryng™ with OsteoCushion™ Technology is the name of a product we provide.

How can I learn more about spryng™ and Petvivo?

If you are a potential investor or have investor-related questions regarding spryng™ or PetVivo, please contact PetVivo's president, John Lai at (952)-681-7681 or by email: JLAI@PETVIVO.COM

If you are a certified and licensed veterinarian, you can order spryng™ here.

If you are an animal owner, spryng™ is available for your animal through certain licensed and certified veterinarians. To locate a veterinarian in your area who can administer spryng™ to your animal, please email us: INFO1@PETVIVO.COM

What if I have more questions?

We're ready to answer and address any questions or concerns. Whether by phone, e-mail, mail, and more, you can contact us here.